ABSTRACT
A simple and sensitive spectrofluorimetric method has been developed for the determination of deflazacort in pharmaceutical tablet dosage forms. The method was based on the liebermann-burchard reaction, in which the chloroform extract of deflazacort is reacted with acetic anhydride and sulfuric acid to produce strong fluorescence. The resulting fluorophor exhibit excitation and emission wavelengths at 300 and 435 nm, respectively. Linear relationship for the fluorescence intensity was obtained in the concentration range of 0.5 - 10 μg/ml. The method was validated in terms of linearity (0.5-10 μg/ml), repeatability (RSD, 0.99 %), precision (intra-day variation, RSD, 0.239 to 1.287 % and inter-day variation, RSD, 0.360 to 1.830 %) and accuracy (99.12 to 100.28 %). The limit of detection and limit of quantification for deflazacort were found to be 0.15 and 0.45 85.70 μg/ml, respectively. The developed method was successfully used for the assay of deflazacort tablet formulation. The spectrofluorimetric method was found to be simple, sensitive, accurate, precise and economic and can be used for the routine quality control testing of deflazacort in tablet dosage form.
ABSTRACT
A simple and sensitive high performance thin layer chromatography (HPTLC) method has been developed for the quantitative estimation of deflazacort in its single component tablet formulation (30 mg). Deflazacort was chromatographed on silica gel 60 F254 TLC plate using benzene: methanol: glacial acetic acid (7.5:2.0:0.5, v/v/v) as mobile phase. Deflazacort showed Rf value of 0.60 + 0.02 and scanned at 243 nm using a camag TLC scanner 3. The method was validated in terms of linearity (100 – 800 ng/spot), precision (intra-day variation, 0.335 to 1.203% and inter-day variation, 0.231 to 1.471%), accuracy (98.87 to 99.77%) and specificity. The limit of detection and limit of quantification for deflazacort were found to be 25.97 ng/spot and 85.70 ng/spot, respectively. The developed method was successfully used for the assay of deflazacort tablet formulation. The method was found to be simple, sensitive, specific, accurate and precise and can be used for the routine quality control testing of deflazacort in tablet dosage form.